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ABSTRACT
Objectives: Embryo implantation represents the major limiting step during in vitro fertilization (IVF) procedure. Immu-
nological and coagulation abnormalities were shown to have a substantial part in multifactorial etiology of IVF failure. We 
aimed to investigate the effect of short-term low-dose dexamethasone plus acetylsalicylic acid (ASA) treatment, starting 
at the time of embryo transfer, on the implantation and clinical pregnancy rates in general IVF population.
Material and methods: Out of 233 consecutive patients undergoing fresh IVF/intracytoplasmic sperm injection (ICSI) cycles 
64 received an adjuvant treatment consisting of dexamethasone (0.5 mg/day) plus ASA (100 mg/day) (DA group), starting 
on the day of embryo transfer. Patients not receiving these medications comprised a control group.
Results: Significantly more patients in DA group had positive ß-hCG values than controls (59.38% vs. 37.67%, p = 0.004) 
(OR = 2.42, 95% CI: 1.33–4.41). Implantation rate was 26.53% in DA group and 15.92% in controls (p = 0.0294). Clinical preg-
nancy rate per started cycle was higher in DA group (43.59%) than controls (28.92%), but the difference was not significant 
(p = 0.0879; OR = 1.99, 95% CI: 0.89–4.41).
Conclusions: Our study shows a potential benefit of dexamethasone plus ASA adjuvant treatment in females undergoing 
IVF/ICSI procedure. As these results show improvement of IVF outcome, a greater number of patients undergoing this type 
and regime of adjuvant treatment should be investigated.
Key words: embryo implantation; pregnancy rate; assisted reproductive techniques; spontaneous abortion; coagulation 
disorders; glucocorticoid effects
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INTRODUCTION
In vitro fertilization (IVF) procedure is still a challeng-
ing process with embryo implantation being the major 
limiting step for its success. Implantation depends on the 
quality of embryo and endometrial receptivity. In order 
to enhance receptivity various adjuvant treatments have 
been investigated. Immunological factors and maternal 
thrombophilia were shown to have a substantial part in 
multifactorial etiology of IVF failure and early miscarriage. 
In this respect, immunosuppressants and anti-thrombotic 
agents have been tested [1, 2].
Many studies evaluated the effect of acetylsalicylic 
acid (ASA) supplementation in females undergoing IVF 
treatment, however without general conclusion [2, 3]. It is 
suggested that low-dose aspirin could increase implanta-
tion rates through its anti-thrombotic effect on the newly 
formed microvasculature, reduced vascular resistance, and 
ameliorated blood perfusion, as well as an increase in oo-
cyte maturation. Better blood supply of the uterus leads to 
an increase of endometrial thickness which is prerequisite 
for implantation [4, 5]. Also, certain autoantibodies, such 
as antiphospholipid and anti-β2-glycoprotein I antibodies, 
may predispose to the placental thrombosis in which case 
anticoagulants are used [6].
Glucocorticoids (GCs) as immunosuppressants and 
anti-inflammatory agents are proposed to improve implan-
tation by acting on the uterine natural killer (uNK) cells, 
cytokine expression, and suppression of inflammation [4, 7]. 
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They cause down-regulation of pro-inflammatory cytokines 
while up-regulating anti-inflammatory molecules. Gluco-
corticoids also inhibit phagocytosis of macrophages and 
induce apoptosis in distinct subsets of T lymphocytes, while 
having less effect on humoral immunity and antibodies 
production [8, 9]. Dexamethasone was determined to cause 
profound and rapid decrease in circulating monocytes and 
lymphocytes, as well as lymphocyte apoptosis. On the other 
hand, GCs may also have a positive effect on the immune 
system, for example, when concurrently acting with other 
activation-induced signals they support the survival of 
T lymphocytes [10, 11].
However, treatment with GC and ASA medications cre-
ates a potential risk for adverse effects (easier develop-
ment of an infection, endocrine and metabolic disturbances, 
bleeding problems, etc.) [3, 12]. There is no general agree-
ment about the dosage, time to start, and the length of 
the GCs or ASA treatment [7, 13]. Thus, it is important to 
determine an effective and safe protocol that would be 
optimal to improve the outcome of IVF and minimize the 
chances of side effects.
Objectives
The aim of our study was to investigate the effect of 
short-term low-dose dexamethasone plus ASA treatment, 
starting at the time of embryo transfer (ET), on the implanta-
tion and pregnancy rates in general IVF population.
MATERIAL AND METHODS
Participants and protocol
Our prospective case-control study included 233 con-
secutive patients undergoing fresh IVF/ intracytoplasmic 
sperm injection (ICSI) cycle, at the Gynecology and Obstet-
rics Clinic, Clinical Center in Nis, Serbia, between September 
2017 and October 2018. The principles of the Helsinki Dec-
laration were applied, along with the Medical Faculty Ethics 
Committee approval (under No. 12-2307-2/15, 10.03.2016).
The participants were allocated to either the group 
receiving adjuvant dexamethasone plus ASA treatment, 
called DA group or to a group receiving only standard 
treatment, as the control group. Inclusion criteria for 
the DA group were: spontaneous abortion, inherited 
thrombophilia (heterogenous and homogenous, as well 
as compound heterozygous polymorphisms in MTHFR 
(C677T and A1298C) or PAI-1 gene (4G/5G), acquired 
thrombophilia (anticardiolipin antibodies and lupus 
anticoagulant), increased coagulation factor I or II lev-
els, decreased antithrombin III, protein C and S levels, 
anti-nuclear and anti-thyroglobulin antibodies. Patients 
in the DA group were provided with detailed informa-
tion regarding dexamethasone plus ASA treatment, as 
a concomitant therapy during ART procedure at the Clinic. 
They decided whether to receive this additional therapy 
and signed informed consent.
Exclusion criteria was low-molecular weight heparin 
(LMWH) use for inherited thrombophilia with homozygous, 
heterozygous or compound heterozygous mutations in 
coagulation factor V (G1691A — Leiden) and prothrombin 
G20210A gene, according to appropriate guidelines [14]. 
Control group comprised patients that did not have 
thrombophilia or any immunologic condition, thus they 
were not requiring LMWH, ASA or glucocorticoids.
All participants underwent stimulation with “short” 
or “long” protocol with gonadotropin-releasing hormone 
(GnRH) agonists or antagonists plus gonadotropins, at ap-
propriate doses. Ovarian response was monitored by serial 
transvaginal ultrasound, with a Shimadzu ultrasound de-
vice, starting on the 6th day of stimulation and two serum 
E2 level measurements. When two or more follicles reached 
18 mm an injection of 10.000 IU of human chorionic go-
nadotropin (hCG) was given i.m or s.c., and a transvagi-
nal ultrasound-guided oocytes aspiration was performed 
34–36 hours afterwards. Either IVF or ICSI was done accord-
ing to the clinical indications. Embryo quality was assessed 
by the day 3 or day 5 embryo grading system, based on the 
number and size of the cells and the fragmentation rate or by 
grading the components of the blastocyst. Embryo transfer 
was done on day 2, 3, or 5 after the aspiration according to 
the embryo quality. Maximally 3 embryos were transferred 
into the uterus. Thereafter, all patients were supplemented 
with progesterone therapy 200 mg 3 times a day, vaginally.
Administration of both adjuvant medications started on 
the day of embryo transfer: dexamethasone in the dose of 
0.5 mg per day and ASA 100 mg per day. Dexamethasone 
treatment lasted until the end of the 12th week of gestation, 
while the ASA treatment continued until delivery.
Twelve days after ET, the serum ß-hCG was deter-
mined for biochemical verification of pregnancy (if above 
25 mIU/mL and rising). Clinical pregnancy was assessed 
5–6 weeks after the ET by detection of a gestational sac, nor-
mal embryonic echo, and cardiac pulsation, using a trans-
vaginal ultrasound.
Implantation rate was defined as the number of ges-
tational sacs observed divided by the number of embryos 
transferred. Clinical pregnancy rate represented the percent-
age of IVF procedures with a favourable outcome, preg-
nancy per started cycle.
Statistical analysis
The results were expressed in percentages, means ± stand-
ard deviations (SD) or medians ± interquartile range (IQR), as 
required. Pearson’s χ² test was used to determine whether 
there is a significant difference between the groups. Fischer 
exact test was used when the frequency of a category was 
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5 or less. The risk was estimated by the odds ratio (OR) with 
95% confidence interval (CI). According to the Shapiro-Wilk 
normality test, Student’s t-test or Mann-Whitney U test 
was used. Statistical analyses were performed using SPSS 
17.0 (SPSS, Chicago, IL, USA) statistical program.
RESULTS
Out of 233 patients, 64 received adjuvant dexametha-
sone plus ASA treatment, while 146 patients comprised the 
control group. Twenty-three patients were excluded due to 
unperformed embryo transfer. IVF or ICSI procedure was 
done in 80.7% and 19.3% of patients in the DA group, and 
82.55% and 17.45% in the control group, respectively. No 
adverse effects of the adjuvant treatment were reported. 
Patients’ basal characteristics are presented in Table 1. 
There was no significant difference between the groups 
concerning age, body mass index, infertility period, infertil-
ity etiology, endometrial thickness, mean serum hormone 
levels, number and quality of embryos. 
No significant difference was found in stimulation proto-
cols between the DA and control group. Patients in DA group 
most frequently underwent GnRH agonist — long protocol 
(54.7%) compared to GnRH agonist — short (10.9%) and 
antagonist (34.4%) protocol, while the protocol frequencies 
in control group were following: 46.6%, 14.4%, and 39.0%, 
respectively. The doses of gonadotropins were significantly 
higher in DA group than controls, but this would not influ-
ence adjuvant treatment effect on implantation process as 
this treatment started on the day of ET and there was no 
difference in the mean number and quality of transferred 
embryos between the groups.
Significantly more patients in DA group had positive 
ß-hCG values than controls (59.38% vs. 37.67%; chi = 8.4948, 
p = 0.00356) (OR = 2.42, 95% CI: 1.33–4.41). 
When patients were analyzed according to the quality of 
transferred embryos, the difference between DA and control 
group for those with good quality embryos was significant 
(p = 0.0087), but for poor quality embryos, the difference 
was not significant (p = 0.0993).
Implantation rate was 26.53% in DA group and 
15.92% in controls, which was statistically significant for 
p = 0.0294. Clinical pregnancy rate per started cycle was 
higher in DA group (43.59%) than in controls (28.92%), but 
insignificant (p = 0.0879, OR = 1.99, 95% CI: 0.89–4.41). 
Twin pregnancies were slightly higher in DA group (15.79%) 
than controls (8.43%) (difference not significant).
DISCUSSION
Approximately 10 days after fertilization syncytiotropho-
blast reaches the capillaries of the endometrium and ma-
ternal blood fulfils the lacunae. The implantation process 
is finished by the second week following fertilization [15]. 
Inadequate trophoblast invasion may be caused by many 
factors among which chromosomal anomalies, immune or 
thrombophilic disorders are most frequent [1]. Thus, it is 
supposed that immunologic aberrations and altered blood 
flow may be responsible for many cases of unexplained 
infertility and recurrent pregnancy losses. 
Studies that investigated the effects of GCs, ASA or their 
combination gained various results concerning ovarian re-
sponse and IVF success. Most analyses and evidence do not 
support the routine use of these medications in ART [3, 16].
Results on aspirin effects on IVF outcome measures are 
found both beneficial and insignificant. In most studies, 
aspirin dose was 100 mg starting along with controlled 
ovarian hyperstimulation [3]. Two meta-analyses found no 
beneficial effect of aspirin on clinical pregnancy or live birth 
rates [2, 3]. However, it is also reported that low-dose aspirin 
improves uterine artery pulsatility index and blood flow 
velocity, ovarian responsiveness, high-quality embryos rate, 
implantation and clinical pregnancy rates [2, 4, 17].
Table 1. Basal characteristics of studied groups
Variables DA group(n = 64)
Control group
(n = 146) p
Age [years] 34.80 ± 4.06 36.29 ± 4.67 ns
BMI [kg/m2] 23.04 ± 2.88 24.01 ± 3.62 ns
Duration of infertility 
[years] 6.85 ± 3.88 5.47 ± 3.25 ns
Total Gn dose [IU] 2533.53 ± 1134.5 1738.79 ± 729.8 < 0.05
Endometrial thickness 
2 days prior ET [mm] 9.37 ± 1.46 9.75 ± 1.78 ns
Mean serum E2 203.5 ± 157.0 196.4 ± 155.9 ns
Mean serum LH 5.22 ± 2.07 6.26 ± 3.20 ns
Mean serum FSH 7.95 ± 3.46 8.00 ± 3.73 ns
Mean transferred 
embryo number 2.60 ± 0.65 2.44 ± 0.69 ns
Mean top quality 
embryo number 1.45 ± 1.25 1.54 ± 1.31 ns
Levothyroxine treated 
hypothyreosis 5 (10.20%) 32 (20.38%) ns
Bromocriptine treated 
hyperprolactinemia 3 (6.12%) 18 (11.46%) ns
Causes of infertility n [%] n [%]
Reduced ovarian  
reserve / Ovulatory 6 (12.24%) 23 (14.65%) ns
Tubal disease 10 (20.41%) 28 (17.83%) ns
Idiopathic infertility 17 (34.69%) 49 (31.21%) ns
PCOS 7 (14.29%) 20 (12.74%) ns
Male related infertility 18 (36.73%) 56 (35.67%) ns
Previous 
endometriosis 1 (2.04%) 7 (4.46%) ns
BMI — body mass index; DA — dexamethasone plus acetylsalicylic acid;  
ET — embryo transfer; Gn — Gonadotropins; ns — not significant;  
PCOS — polycystic ovary syndrome
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There is inconsistent evidence of dexamethasone and 
aspirin safety in IVF patients. In a meta-analysis of 13 trials, 
there was no significant difference in miscarriage or vaginal 
bleeding between groups that used aspirin or placebo [3]. 
In our study, there were no reported side effects of this 
treatment. Low-dose aspirin (app. 100 mg/day) seems to 
provide optimal platelets selective effect without changing 
the bleeding time [18]. Aspirin shifts local production of 
thromboxane A2 towards prostacyclin I2 creating vasodila-
tation which is necessary for the embryo implantation [17].
Prednisone is a proposed treatment for immunologic 
dysregulation in couples with recurrent miscarriage. Also, 
GCs were found beneficial in a group of patients with au-
toantibodies undergoing IVF, while their use in general IVF 
population showed ambiguous action [1, 19]. In a couple 
of studies, GCs increased clinical pregnancy rate without 
changing live birth rate [7, 19–21], whilst in the study of Liu 
et al. [22] there was no difference in clinical pregnancy rate 
but with the significantly higher cumulative live-birth rate.
Prednisolone treatment was shown to reduce the num-
ber of uNK cells when taken daily from the first day of the 
menstrual cycle [23]. Uterine NK cells make the highest per 
cent of leukocytes in the endometrium, with an increasing 
number during the first trimester. Some studies observed 
an increased number of uNK in patients with recurrent 
miscarriage and recurrent implantation failure [23–25]. 
However, their prognostic value of pregnancy outcome is 
uncertain. Their phenotype and function rather than num-
bers determine the local immune response. Normally uNK 
are non-cytotoxic and involved in angiogenesis, trophoblast 
recognition, and immunotolerance [26]. 
Dexamethasone effect on NK cell response depends 
on the local cytokine milieu. It was shown to enhance the 
proliferation, reactivity, and survival of primary NK cells, that 
were stimulated with IL-2 plus IL-12; while, dexamethasone 
slightly induced primary NK cell death when incubated with 
IL-15 [27]. Uterine NK cells number was significantly corre-
lated with the IL-15/actin and IL-18/IL-18BP ratios, where the 
later was associated with an excess of uNK cells, determined 
in patients with implantation failure [24]. Also, it seems that 
different GCs regulate NK cell responses differently, and their 
action depends on the activation state of lymphocytes as 
well as the nature of additional stimulants present [11, 27]. 
Unlike our study, most studies examined the GC action 
in IVF cycles starting from the day 1 of the downregula-
tion, thus they could assess dexamethasone sensitization 
of ovaries to gonadotropins, which was not applicable here 
[19, 20]. Similar to our study, Duvan et al. [5] used low-dose 
aspirin (100 mg/day) along with prednisolone (10mg/day) 
starting on the ET day (n = 56), but they showed no sig-
nificant differences in implantation and pregnancy rates 
compared to controls. On the contrary, Zhang et al. [25] 
reported the beneficial effect of intrauterine perfusion of 
dexamethasone on clinical pregnancy, for patients with re-
current implantation failure and a high number of uNK cells.
Prednisolone plus ASA treatment was reported to im-
prove IVF outcome in women with autoimmune conditions 
[28, 29]. Ten mg of prednisolone plus 100 mg of aspirin for 
three months before IVF were useful for antinuclear anti-
bodies positive patients [13]. Also, anti-thyroid antibodies 
(ATA) are determined in 10.5% in euthyroid infertile women 
and 13.9% those with idiopathic infertility [28, 30]. IVF pa-
tients treated with levothyroxine, prednisolone, and ASA 
had significantly higher pregnancy and implantation rates 
than untreated or only levothyroxine treated ATA positive 
patients [28, 31]. Doses of prednisolone or dexamethasone 
that had been used as an adjuvant IVF therapy are not 
sufficient to cause reduction of autoantibody titres [13]. 
However, there is no proof that antibodies can directly harm 
pregnancy in human but rather be a sign of a dysregulated 
immune response [1].
Although there was a significantly higher implantation 
rate and per cent of clinical pregnancies in DA patients 
than controls, in our study, the pregnancy rate was not 
statistically significant. The prescribed doses of adjuvant 
medications seem not to interfere with normal endometrial 
recognition of embryo quality and the selection process 
governed by the migration of endometrial stromal cells 
[1, 32]. Implantation frequencies of poor quality embryos 
did not differ significantly between the groups, implying 
that dexamethasone plus ASA did not ease implantation 
of low-viable embryos, which would be potentially harmful.
CONCLUSIONS
Our study shows a potential benefit of the dexametha-
sone plus ASA adjuvant treatment in females undergoing 
fresh IVF/ICSI procedure. Implantation rate was significantly 
increased in DA group than controls, however, the clinical 
pregnancy rate was on the border of statistical significance. 
As these results show improvement of IVF success, a greater 
number of patients undergoing this type and regimen of 
adjuvant treatment should be investigated.
Acknowledgements
The work is supported by Project No. III 41018 of the Ministry 
of Education, Science and Technological Development of 
Republic of Serbia; and the Project No. 3 of the Faculty of 
Medicine University of Nis Serbia.
REFERENCES
1. Larsen EC, Christiansen OB, Kolte AM, et al. New insights into mecha-
nisms behind miscarriage. BMC Med. 2013; 11: 154, doi: 10.1186/1741-
7015-11-154, indexed in Pubmed: 23803387.
2. Khairy M, Banerjee K, El-Toukhy T, et al. Aspirin in women undergoing in 
vitro fertilization treatment: a systematic review and meta-analysis. Fer-
205
Dejan Mitic et al., Dexamethasone plus ASA in IVF
www. journals.viamedica.pl/ginekologia_polska
til Steril. 2007; 88(4): 822–831, doi:  10.1016/j.fertnstert.2006.12.080, 
indexed in Pubmed: 17509593.
3. Siristatidis CS, Basios G, Pergialiotis V, et al. Aspirin for in vitro 
fertilisation. Cochrane Database Syst Rev. 2016; 11: CD004832, 
doi: 10.1002/14651858.CD004832.pub4, indexed in Pubmed: 27807847.
4. Hasegawa I, Yamanoto Y, Suzuki M, et al. Prednisolone plus low-dose 
aspirin improves the implantation rate in women with autoimmune 
conditions who are undergoing in vitro fertilization. Fertility and Sterility. 
1998; 70(6): 1044–1048, doi: 10.1016/s0015-0282(98)00343-4.
5. Duvan CI, Ozmen B, Satiroglu H, et al. Does addition of low-dose 
aspirin and/or steroid as a standard treatment in nonselected intracy-
toplasmic sperm injection cycles improve in vitro fertilization success? 
A randomized, prospective, placebo-controlled study. J Assist Reprod 
Genet. 2006; 23(1): 15–21, doi: 10.1007/s10815-005-9003-3, indexed in 
Pubmed: 16518579.
6. Ruiz-I rastorza G,  Crowther M, Branch W, et  al.  Antiphos-
pholipid syndrome. The Lancet. 2010; 376(9751): 1498–1509, 
doi: 10.1016/s0140-6736(10)60709-x.
7. Boomsma CM, Eijkemans M, Keay SD, et al. Peri-implantation 
glucocorticoid administration for assisted reproductive technol-
ogy cycles. Cochrane Database Syst Rev. . 2012(6): CD005996, 
doi: 10.1002/14651858.CD005996.pub3.
8. Pelaia G, Vatrella A, Cuda G, et al. Molecular mechanisms of corticosteroid 
actions in chronic inflammatory airway diseases. Life Sciences. 2003; 
72(14): 1549–1561, doi: 10.1016/s0024-3205(02)02446-3.
9. Schimmer BP, Funder JW. ACTH. Adrenal Steroids, and Pharmacology 
of the Adrenal Cortex. In: Brunton LL, Chabner BA, Knollmann BC. ed. 
Goodman and Gilman’s: The Pharmacological Basis of Therapeutics. 12th 
ed. McGraw-Hill Companies Inc, New York 2011: 1209–1235.
10. Parrillo JE, Fauci AS. Mechanisms of corticosteroid action on lymphocyte 
subpopulations. III. Differential effects of dexamethasone administration 
on subpopulations of effector cells mediating cellular cytotoxicity in 
man. Clin Exp Immunol. 1978; 31(1): 116–125.
11. Perez SA, Mahaira LG, Demirtzoglou FJ, et al. A potential role 
for hydrocortisone in the positive regulation of IL-15-activated 
NK-cell proliferation and survival. Blood. 2005; 106(1): 158–166, 
doi: 10.1182/blood-2004-08-3232, indexed in Pubmed: 15755904.
12. Akhanoba F, MacDougall J, Mathur R, et al. Severe systemic candidiasis 
following immunomodulation therapy in in vitro fertilisation-embryo 
transfer (IVF-ET). BMJ Case Rep. 2014; 2014, doi:  10.1136/bcr-2013-
203202, indexed in Pubmed: 24686802.
13. Zhu Q, Wu Li, Xu Bo, et al. A retrospective study on IVF/ICSI outcome 
in patients with anti-nuclear antibodies: the effects of prednisone plus 
low-dose aspirin adjuvant treatment. Reprod Biol Endocrinol. 2013; 
11: 98, doi: 10.1186/1477-7827-11-98, indexed in Pubmed: 24093222.
14. American College of Obstetricians and Gynecologists Women’s Health 
Care Physicians. ACOG Practice Bulletin No. 138: Inherited thrombophili-
as in pregnancy. Obstet Gynecol. 2013; 122(3): 706–717, doi: 10.1097/01.
AOG.0000433981.36184.4e, indexed in Pubmed: 23963422.
15. Rendi M, Muehlenbachs A, Garcia R, et al. Female Reproductive System. 
Comparative Anatomy and Histology. 2012: 253–284, doi: 10.1016/b978-
0-12-381361-9.00017-2.
16. Dentali F, Ageno W, Rezoagli E, et al. Low-dose aspirin for in vitro fertiliza-
tion or intracytoplasmic sperm injection: a systematic review and a me-
ta-analysis of the literature. J Thromb Haemost. 2012; 10(10): 2075–2085, 
doi: 10.1111/j.1538-7836.2012.04886.x, indexed in Pubmed: 22900525.
17. Rubinstein M. Low-dose aspirin treatment improves ovarian respon-
siveness, uterine and ovarian blood flow velocity, implantation, and 
pregnancy rates in patients undergoing in vitro fertilization: a prospec-
tive, randomized, double-blind placebo-controlled assay. Fertility and 
Sterility. 1999; 71(5): 825–829, doi: 10.1016/s0015-0282(99)00088-6.
18. Clarke RJ, Mayo G, Price P, et al. Suppression of thromboxane A2 but not 
of systemic prostacyclin by controlled-release aspirin. N Engl J Med. 1991; 
325(16): 1137–1141, doi: 10.1056/NEJM199110173251605, indexed in 
Pubmed: 1891022.
19. Boomsma CM, Macklon NS. Does glucocorticoid therapy in the peri-im-
plantation period have an impact on IVF outcomes? Curr Opin Obstet 
Gynecol. 2008; 20(3): 249–256, doi:  10.1097/GCO.0b013e3282f8aff5, 
indexed in Pubmed: 18460939.
20. Keay SD, Lenton EA, Cooke ID, et al. Low-dose dexamethasone augments 
the ovarian response to exogenous gonadotrophins leading to a reduc-
tion in cycle cancellation rate in a standard IVF programme. Human Re-
production. 2001; 16(9): 1861–1865, doi: 10.1093/humrep/16.9.1861.
21. Kalampokas T, Pandian Z, Keay SD, et al. Glucocorticoid supplementation 
during ovarian stimulation for IVF or ICSI. Cochrane Database Syst Rev. 
2017; 3: CD004752, doi: 10.1002/14651858.CD004752.pub2, indexed 
in Pubmed: 28349525.
22. Liu S, Shi L, Wang T, et al. Effect of low-dose dexamethasone on patients 
with elevated early follicular phase progesterone level and pregnancy 
outcomes in IVF-ET treatment: A randomized controlled clinical trial. 
Clin Endocrinol (Oxf ). 2018; 89(6): 771–778, doi:  10.1111/cen.13824, 
indexed in Pubmed: 30051499.
23. Quenby S, Kalumbi C, Bates M, et al. Prednisolone reduces preconceptual 
endometrial natural killer cells in women with recurrent miscarriage. 
Fertil Steril. 2005; 84(4): 980–984, doi: 10.1016/j.fertnstert.2005.05.012, 
indexed in Pubmed: 16213853.
24. Lédée-Bataille N, Bonnet-Chea K, Hosny G, et al. Role of the endome-
trial tripod interleukin-18, -15, and -12 in inadequate uterine receptiv-
ity in patients with a history of repeated in vitro fertilization-embryo 
transfer failure. Fertil Steril. 2005; 83(3): 598–605, doi: 10.1016/j.fertns-
tert.2004.11.021, indexed in Pubmed: 15749487.
25. Zhang T, Huang C, Du Y, et al. Successful treatment with intrauterine 
delivery of dexamethasone for repeated implantation failure. Am 
J Reprod Immunol. 2017; 78(6), doi:  10.1111/aji.12766, indexed in 
Pubmed: 28921750.
26. Kalkunte SS, Mselle TF, Norris WE, et al. VEGF C facilitates immune 
tolerance and endovascular activity of human uterine NK cells at 
the maternal-fetal interface. J Immunol. 2009; 182(7): 4085–4092, 
doi: 10.4049/jimmunol.0803769.
27. Morgan DJ, Davis DM. Distinct Effects of Dexamethasone on Human Nat-
ural Killer Cell Responses Dependent on Cytokines. Front Immunol. 2017; 
8: 432, doi: 10.3389/fimmu.2017.00432, indexed in Pubmed: 28450865.
28. Revelli A, Casano S, Piane LD, et al. A retrospective study on IVF outcome 
in euthyroid patients with anti-thyroid antibodies: effects of levothyrox-
ine, acetyl-salicylic acid and prednisolone adjuvant treatments. Reprod 
Biol Endocrinol. 2009; 7: 137, doi: 10.1186/1477-7827-7-137, indexed in 
Pubmed: 19941670.
29. Taniguchi F. Results of prednisolone given to improve the outcome of in 
vitro fertilization-embryo transfer in women with antinuclear antibod-
ies. J Reprod Med. 2005; 50(6): 383–388.
30. Poppe K, Velkeniers B, Glinoer D. Thyroid disease and female reproduc-
tion. Clin Endocrinol (Oxf ). 2007; 66(3): 309–321, doi: 10.1111/j.1365-2
265.2007.02752.x, indexed in Pubmed: 17302862.
31. Weghofer A, Himaya E, Kushnir VA, et al. The impact of thyroid func-
tion and thyroid autoimmunity on embryo quality in women with 
low functional ovarian reserve: a case-control study. Reprod Biol 
Endocrinol. 2015; 13: 43, doi: 10.1186/s12958-015-0041-0, indexed in 
Pubmed: 25975563.
32. Teklenburg G, Salker M, Molokhia M, et al. Natural selection of hu-
man embryos: decidualizing endometrial stromal cells serve as sensors 
of embryo quality upon implantation. PLoS One. 2010; 5(4): e10258, 
doi: 10.1371/journal.pone.0010258, indexed in Pubmed: 20422011.
